





**ORALTEK**<sup>®</sup> sublingual immunotherapy with glycerinated native extracts dispensed in a spray to cover a larger surface area of the oral mucosa.

The atomisation of the spray provides access to a larger number of antigen-presenting cells (dendritic cells)<sup>1</sup>





86% of patients experienced an improvement in their well-being after 1 year of treatment with ORALTEK®2

ALLERGIC SYMPTOMS

Rhinitis
Conjunctivitis
Asthma

REDUCED
BY **50%** ON
AVERAGE
(in all cases p<0.005)



ORALTEK® treatment was well tolerated by patients<sup>2</sup>

ONLY 1 MILD LOCAL ADVERSE REACTION WAS REPORTED



GOOD ADHERENCE:
ONLY 3 PATIENTS
DISCONTINUED
TREATMENT



Multicentre cohort study evaluating safety and adherence to treatment in patients with allergic rhinitis, conjunctivitis or mild asthma (N=64)

## Maintenance dose on 1st day<sup>3</sup>



## 2 sprays under your tongue once daily

2 bottles of 9 mL (30,000 TU/mL) Each spray dispenses 0.1 mL Approximate duration of treatment (2 vials): 3 months

## Allergens available



Oraltek® 2 BOTTLES OF 9 mL

30,000 TU/mL

\*Therapeutical Units



POLLEN
6 Grasses <sup>4</sup>
2 Grasses⁵
Cynodon dactylon
Lolium perenne
Olea europaea
Cupressus arizonica
Platanus hispanica
Artemisia vulgaris
Chenopodium album
Parietaria judaica
Salsola kali
DUST MITES
Dermatophagoides
(D. pteronyssinus, D. farinae)
D. pteronyssinus
D. pteronyssinus  D. farinae
. ,
D. farinae
D. farinae Lepidoglyphus destructor
D. farinae Lepidoglyphus destructor Tyrophagus putrescentiae
D. farinae Lepidoglyphus destructor Tyrophagus putrescentiae Blomia tropicalis
D. farinae Lepidoglyphus destructor Tyrophagus putrescentiae Blomia tropicalis DANDER
D. farinae Lepidoglyphus destructor Tyrophagus putrescentiae Blomia tropicalis DANDER Cat
D. farinae Lepidoglyphus destructor Tyrophagus putrescentiae Blomia tropicalis DANDER Cat Dog







**ORALTEK**<sup>®</sup> is a sublingual immunotherapy product.

 $\textbf{Composition:} \ the \ active \ substances \ are \ one \ or \ several \ standardized \ native \ allergen \ extracts \ (30,000 \ TU^*/mL)^{**}.$ 

**Excipients:** glycerol, sodium chloride, artificial pineapple flavouring and water for injection.

Pharmaceutical form: sublingual spray, solution.

**Presentations:** 1 bottle of 6 mL or 2 bottles of 9 mL; adequate for approximately 1- and 3-months treatment, respectively. It is packed in amber glass bottles containing a spray pump and a nozzle.

Therapeutic indications: ORALTEK® is indicated for adults and children to treat type I allergic diseases (IgE-mediated), such as rhinitis/rhinoconjunctivitis and bronchial asthma.

**Method of administration: ORALTEK®** is administered sublingually. Remove the plastic seal from one bottle. Gently shake the bottle. Rotate the nozzle sideways. Spray 3 or 4 times to ensure the pump mechanism fills up (only when starting the bottle). Lift your tongue and direct the nozzle under your tongue and spray twice to apply the appropriate dose. Retain the dose under your tongue, for approximately 1-2 minutes before swallowing. Rotate the nozzle back to its original vertical position, thereby locking the spray mechanism.

**ORALTEK®** must be administered as separate as possible from the intake of food and drinks (at least 30 minutes prior to and after the consumption of food and/or drink). Do not brush your teeth or rinse the mouth within the 30 minutes prior to or after administration.

Storage: store in a refrigerator (2-8°C). Keep out of sight and reach of children.

Revised: March 2022.

\*TU: Therapeutic Units.

\*\* Mixture of Dermatophagoides (Dermatophagoides pteronyssinus + Dermatophagoides farinae) and grass mixture (Dactylis glomerata + Trisetum peniceum, Dactylis glomerata + Poa pratensis + Holcus lanatus + Festuca elatior + Phleum pratense + Lolium perenne) are considered as a single allergen.





<sup>1.</sup> Allam JP, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy, 2008. 63(6):720-7.

<sup>2.</sup> Köhlmoos C, et al. Sicherheit und Compliance einer sublingualen Immuntherapie mit Spray-Applikation. Poster 54. Allergo J 2009; 18.

<sup>3.</sup> SmPc ORALTEK®